Innovent biologics drug meets primary endpoint in macular degeneration trial
Tweet Send to a Friend
Innovent Biologics Inc. (HKEX: 01801) announced that its Phase 3 clinical study of efdamrofusp alfa injection met the primary endpoint ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
